Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.6 NOK | 0.00% | +4.44% | -9.40% |
Sales 2024 * | 171M 15.57M | Sales 2025 * | 203M 18.53M | Capitalization | 580M 52.95M |
---|---|---|---|---|---|
Net income 2024 * | -11M -1M | Net income 2025 * | -6M -548K | EV / Sales 2024 * | 3.2 x |
Net cash position 2024 * | 34M 3.1M | Net cash position 2025 * | 15M 1.37M | EV / Sales 2025 * | 2.78 x |
P/E ratio 2024 * |
-50.3
x | P/E ratio 2025 * |
-88.3
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.85% |
Latest transcript on Gentian Diagnostics
1 week | +4.44% | ||
Current month | -3.09% | ||
1 month | -6.70% | ||
3 months | -13.16% | ||
6 months | -7.84% | ||
Current year | -9.40% |
Managers | Title | Age | Since |
---|---|---|---|
Hilja Ibert
CEO | Chief Executive Officer | - | 18-07-15 |
Njaal Kind
DFI | Director of Finance/CFO | 52 | 18-01-01 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Settevik
CHM | Chairman | 64 | - |
Fredrik Thoresen
BRD | Director/Board Member | 44 | - |
Director/Board Member | 60 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 37.6 | 0.00% | 0 |
24-04-24 | 37.6 | 0.00% | 2,850 |
24-04-23 | 37.6 | +2.73% | 125 |
24-04-22 | 36.6 | 0.00% | 187 |
24-04-19 | 36.6 | +1.67% | 9,135 |
Real-time Oslo Bors, April 25, 2024 at 10:45 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.40% | 52.72M | |
-1.09% | 12.72B | |
-12.53% | 7.5B | |
+0.45% | 5.48B | |
-1.37% | 4.61B | |
+5.16% | 4.47B | |
-51.93% | 3.28B | |
+11.34% | 2.71B | |
-19.05% | 2.02B | |
-11.07% | 1.74B |
- Stock Market
- Equities
- GENT Stock